Review
Version 1
Preserved in Portico This version is not peer-reviewed
Challenges of Iron Chelation in Thalassemic Children
Version 1
: Received: 27 December 2023 / Approved: 27 December 2023 / Online: 27 December 2023 (15:51:44 CET)
A peer-reviewed article of this Preprint also exists.
Adramerina, A.; Economou, M. Challenges of Iron Chelation in Thalassemic Children. Thalass. Rep. 2024, 14, 1-9. Adramerina, A.; Economou, M. Challenges of Iron Chelation in Thalassemic Children. Thalass. Rep. 2024, 14, 1-9.
Abstract
Thalassemia treatment still relies on supportive care, including mainly blood transfusion and iron chelation therapy. Iron chelation therapy is considered the main responsible factor for the marked improvement in survival of thalassemic patients. Hemosiderosis should be prevented with appropriate chelation therapy from early childhood, timely dose adjustment according to changing body weight, as well as close monitoring of organ iron overload. Three iron chelators are currently available and the choice of appropriate chelator or their combination in pediatric population is individualized, depending on iron overload in target organs, patient age, adverse events and compliance issues, due to the limitations in their administration.
Keywords
thalassemia; deferoxamine; deferiprone; deferasirox
Subject
Medicine and Pharmacology, Pediatrics, Perinatology and Child Health
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
